Tofersen update - NICE initial appraisal decision
Thursday, 19 November 2026
Research
We are disappointed that following the initial appraisal of tofersen by the National Institute for Health and Care Excellence (NICE), the committee has reached a preliminary decision not to recommend NHS funding of tofersen for treating amyotrophic lateral sclerosis (the most common form of MND) caused by SOD1 gene mutations.
The NICE technology appraisal committee met with MND clinical and patient experts, as well as the company that developed the drug (Biogen) on 22 October 2026, followed by a closed meeting where the committee reached their decision. The clinical and patient representatives that attended the meeting provided a robust and powerful narrative of the impact of tofersen, which was appreciated by the NICE committee. However, following the meeting, the committee has requested additional analyses from Biogen to better reflect the SOD1 population, and provide more certainty that tofersen is providing value for money within the NHS.
This outcome was not unexpected and is often seen with drugs that are assessed through this highly specialised committee. Tofersen is the most effective treatment for MND that has ever been developed, and this has been confirmed by clinical and patient experts. We will continue to lobby for its approval on the NHS and do everything we can to support the next stages of NICE's decision.
Professor Ammar Al-Chalabi, Professor of Neurology and Complex Disease Genetics at King's College London said: “It is not unusual for very specialist treatments like tofersen to go through more than one round of appraisal, and so, while this initial news is not what we wanted, people should remain hopeful. The NICE committee did listen carefully to the patient experts and to us as clinical experts, and I am sure that they will come to a fair conclusion when the process is completed.”
Professor Chris McDermott, Professor of Translational Neurology at the Sheffield Institute for Translational Neuroscience said: "Tofersen is the single most effective treatment for MND I have seen throughout my career as a neurologist. To read the news that NICE has decided not to recommend tofersen will undoubtedly worry many. As a clinical expert invited to attend the NICE committee meeting, I did feel that the NICE committee understood the impact tofersen has and I am hopeful that by the time the complex multistage NICE appraisal concludes we will see a final decision which makes tofersen available to patients with SOD1 MND."
You can find the NICE draft guidance here, and further information on their website here.
We will share more information as soon as it is available.